Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.
Leveraging unique technology for creating novel microalgae strains from the environment, we provide microalgae strains useful for industrial and academic applications. Additionally, we offer; 1: consultation on microalgae business plans and experimental designs, 2: guidance on microalgae cultivation techniques, and 3: evaluation of microalgae strains based on growth rate and produced substances. We collaborate with diverse companies—spanning aquaculture, food, semiconductors, chemical materials, pet supplies, and rare metal recovery—as well as universities and research institutions to create new industries that address global challenges.
HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
A deep tech startup developing a personalized shoe manufacturing platform that integrates 3D scanning, automated design algorithms, and 3D printing. DIFF.3D—which automatically designs optimal footwear from 3D foot scan data and delivers shoes on demand—is set to launch in June 2026. The platform addresses Japan's approximately 25 million "shoe refugees" who struggle to find well-fitting off-the-shelf footwear, while also pursuing a B2B model as an industry infrastructure for other shoe brands.
Our core competence is NanoGAS® technology, which enables the long-term stabilization of nano-scale bubbles over several years. In the healthcare sector, we have leveraged this technology to develop a pioneering Fecal Microbiota Transplantation (FMT) technique. Its efficacy and safety have been validated through "Specific Clinical Research" regarding its impact on Autism Spectrum Disorder (ASD). Furthermore, we have established robust clinical evidence, including a 50% reduction in healing time for pressure ulcers and a 50% decrease in the volume of laxatives required for endoscopic procedures. Beyond medicine, NanoGAS® provides superior oxidation inhibition (anti-corrosion) and antibacterial effects. With a proven track record in maintaining the hygiene of humidifiers, our technology is available for licensing and joint development to dramatically enhance the value of products across diverse fields—from healthcare to industrial and HVAC infrastructure.
